Monkey pox virus bispecific antibody and application thereof
By designing bispecific antibodies targeting the antigen of monkeypox virus M1R and B6R, the problem of lack of specific drugs and vaccines for monkeypox virus in the prior art is solved, and effective treatment of monkeypox virus and other orthopox viruses is achieved and Prevention significantly improves the ability to fight viral infection.
Patent Information
- Application Number
- CN202411329976.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-24
AI Technical Summary
The existing technology lacks specific drugs and vaccines for monkeypox virus, and after the smallpox vaccination is stopped, most people lack resistance to orthopox viruses such as MPXV. The existing medicines have limited efficacy against other orthopox virus infections such as monkeypox. .
A bispecific antibody was designed to use an antibody that inserts the LAIR1 domain between the antibody VH and CH1 by combining the humanized murine antibody h40 targeting the monkeypox virus M1R antigen and the human antibody D21 targeting the B6R antigen. In configuration, antibodies with bispecificity and stronger antiviral infection ability were constructed.
This bispecific antibody can significantly improve the antiviral infection ability and is suitable for the construction of treatment and prevention against monkeypox virus, vaccinia virus, smallpox virus and vaccinia virus. It has broad-spectrum binding ability, can effectively neutralize these viruses and significantly reduce viral load. and increase survival rate.
Smart Images

Figure HDA0005056557500000011 
Figure HDA0005056557500000012 
Figure HDA0005056557500000013
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to monkeypox virus bispecific antibodies and applications thereof. Background Art
[0002] Monkeypox is caused by the monkeypox virus (MPXV), which is a zoonosis that was previously prevalent in Africa. In May 2022, monkeypox broke out globally, caused by infection with MPXV branch IIb. In July 2022, the WHO announced that the monkeypox epidemic constituted an "international public health emergency", and the number of infections is still rising. In addition, this year, monkeypox outbreaks have occurred in many African countries, caused by a new variant branch Ib, which is highly contagious, has severe disease, and a mortality rate of >3%; and the incidence of children has increased significantly. Children under 5 years old in Congo account for 39% of all cases, and the mortality rate is over 7%. On August 14, 2024, the WHO announced that the monkeypox epidemic once again constituted an "international public health emergency".
[0003] Studies have shown that although the smallpox vaccine has a certain degree of immune protection against monkeypox, with the eradication of smallpox and the cessation of vaccination, most people (born after 1980) lack resistance to orthopoxviruses such as MPXV and variola virus (VARV). At present, although chemical drugs such as Tecovirimat and Brincidofovir have been approved for the treatment of smallpox, and vaccinia immunoglobulin (VIG) has been approved for complications caused by smallpox vaccination and can also be used for orthopoxvirus infections such as monkeypox, their efficacy research on other orthopoxvirus infections such as monkeypox is still limited. There are currently no approved drugs and vaccines specific to monkeypox virus.
[0004] MPXV belongs to the genus Orthopoxvirus, which also includes VARV, Vaccinia virus (VACV), and Cowpox virus (CPXV). Infection in humans can cause diseases of varying severity and endanger human health. MPXV has two different forms of infectious virus particles, namely intracellular mature virion (IMV) and extracellular enveloped virion (EEV), which have different envelope structures, infection modes and surface antigens. Among them, the M1R antigen on the surface of IMV and the B6R antigen on the surface of EEV have been shown to induce the production of neutralizing antibodies, making them important targets for research on therapeutic antibodies and vaccines.
[0005] Since MPXV has two different infectious particles, IMV and EEV, and these two different infectious particles have different surface antigens, the combination of antibodies against multiple antigens may have a better antiviral effect. The team's previous research obtained monoclonal neutralizing antibodies against the M1R antigen on the surface of MPXV IMV and the B6R antigen on the surface of EEV. The purpose of this invention is to design bispecific antibodies based on monoclonal antibodies against the M1R antigen and the B6R antigen. Summary of the invention
[0006] The present invention uses humanized mouse anti-h40 targeting monkeypox virus M1R antigen and humanized antibody D21 targeting B6R antigen, and based on the antibody configuration reported in the literature with LAIR1 domain inserted between antibody VH and CH1, successfully constructs a bispecific antibody, which has significantly improved antiviral infection ability compared with the original h40 and D21.
[0007] The antibody has high specificity and is therefore suitable for constructing bispecific antibodies, thereby completing the present invention.
[0008] The present invention provides a bispecific antibody against monkeypox virus, wherein the heavy chain variable region is formed by connecting the heavy chain variable region of a first antibody (h40), the light chain variable region of a second antibody, the heavy chain variable region of the second antibody and a linker; or the heavy chain variable region is formed by connecting the heavy chain variable region of a second antibody (D21), the light chain variable region of a first antibody, the heavy chain variable region of the first antibody and a linker.
[0009] in,
[0010] The three complementary determining regions (CDRs) of the heavy chain variable region of the first antibody (h40) have an amino acid sequence selected from the following group:
[0011] CDR1 (GYIFTRYW) as shown in SEQ ID NO: 1,
[0012] CDR2 (INPSTGYT) as shown in SEQ ID NO: 2, and
[0013] CDR3 (ARSDYTNYVFEY) as shown in SEQ ID NO:3;
[0014] The three complementarity determining regions (CDRs) of the h40 light chain variable region have an amino acid sequence selected from the group consisting of:
[0015] CDR1 (QSLVHSNGNTY) as shown in SEQ ID NO: 4,
[0016] CDR2 (KVS) as shown in SEQ ID NO:5, and
[0017] CDR3 (SQSTHVPYT) as shown in SEQ ID NO:6;
[0018] The three complementary determining regions (CDRs) of the heavy chain variable region of the second antibody (D21) have an amino acid sequence selected from the following group:
[0019] CDR1 (GFSISTYP) as shown in SEQ ID NO:7,
[0020] CDR2 (ISHDGRNK) as shown in SEQ ID NO: 8, and
[0021] CDR3 (ARAYPYAFDV) as shown in SEQ ID NO:9;
[0022] The three complementarity determining regions (CDRs) of the D21 light chain variable region have an amino acid sequence selected from the group consisting of:
[0023] CDR1 (QSVRND) as shown in SEQ ID NO: 10,
[0024] CDR2 (GAS) as shown in SEQ ID NO: 11, and
[0025] CDR3 (QQYKDWPPWT) as shown in SEQ ID NO: 12;
[0026] More preferably, the amino acid sequence of the heavy chain variable region of the first antibody (h40) is SEQ ID NO: 13; the amino acid sequence of the light chain variable region is SEQ ID NO: 14;
[0027] The amino acid sequence of the heavy chain variable region of the second antibody (D21) is SEQ ID NO: 15; the amino acid sequence of the light chain variable region is SEQ ID NO: 16;
[0028] Specifically, the connection mode of the heavy chain variable region of the bispecific antibody is that the heavy chain variable region of the first antibody, the light chain variable region of the second antibody, the linker, and the heavy chain variable region of the second antibody are connected in sequence, wherein the positions of the light chain variable region of the second antibody and the heavy chain variable region of the second antibody can be exchanged; or the connection mode is that the heavy chain variable region of the second antibody, the light chain variable region of the first antibody, the linker, and the heavy chain variable region of the second antibody are connected in sequence, wherein the positions of the light chain variable region of the first antibody and the heavy chain variable region of the first antibody can be exchanged;
[0029] Preferably, the amino acid sequence of the linker is SEQ ID NO: 17;
[0030] Preferably, the amino acid sequence of the heavy chain variable region of the bispecific antibody is SEQ ID NO: 18, and the amino acid sequence of the light chain variable region is SEQ ID NO: 14; or the amino acid sequence of the heavy chain variable region is SEQ ID NO: 19, and the amino acid sequence of the light chain variable region is SEQ ID NO: 16;
[0031] Further preferably, the bispecific antibody further comprises a heavy chain constant region and a light chain constant region; in a specific example, the amino acid sequence of the heavy chain constant region is SEQ ID NO: 20, and the amino acid sequence of the light chain constant region is SEQ ID NO: 21;
[0032] The present invention provides a polynucleotide encoding the aforementioned bispecific antibody;
[0033] The present invention provides an expression vector comprising the above-mentioned polynucleotide;
[0034] The present invention provides a host cell, comprising the above-mentioned expression vector;
[0035] The present invention provides the use of the above-mentioned bispecific antibody in the preparation of a drug for treating and preventing infections caused by orthopoxviruses including but not limited to monkeypox virus, vaccinia virus, smallpox virus, cowpox virus, etc.;
[0036] The present invention provides a pharmaceutical composition comprising the aforementioned bispecific antibody and a pharmaceutical carrier.
[0037] The present invention also provides a pharmaceutical composition containing the bispecific antibody of the monkeypox virus of the present invention. In order to prepare the pharmaceutical composition, the bispecific antibody can be mixed with a pharmaceutical carrier or excipient to prepare various desired dosage forms. As the type of dosage form of the pharmaceutical composition of the present invention, for example, tablets, powders, pills, powders, granules, fine granules, soft / hard capsules, film coatings, pellets, sublingual tablets, ointments, etc. as oral agents can be listed, and as non-oral agents, injections, suppositories, transdermal agents, ointments, plasters, external liquids, etc. can be listed. Those skilled in the art can select appropriate dosage forms according to the route of administration and the subject of administration.
[0038] The dosage of the active ingredient of the pharmaceutical composition of the present invention varies depending on the subject of administration, the subject organ, symptoms, the method of administration, etc., and can be determined based on the doctor's judgment in consideration of the type of dosage form, the method of administration, the age and weight of the patient, the patient's symptoms, etc.
[0039] Beneficial effects of the present invention:
[0040] The present invention constructs and obtains two monkeypox virus bispecific antibodies, which are composed of a monoclonal neutralizing antibody targeting the monkeypox virus M1R antigen and a monoclonal neutralizing antibody targeting the monkeypox virus B6R antigen. They can broadly bind to the monkeypox virus M1R or B6R antigen and proteins homologous to M1R or B6R in vaccinia virus, smallpox virus, and cowpox virus, and can treat orthopoxvirus infections represented by vaccinia virus, and have the potential to treat and prevent orthopoxvirus infections including but not limited to monkeypox virus, vaccinia virus, smallpox virus, cowpox virus, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 : Kinetic curves of antibody #40 binding to MPXV M1R antigen before and after humanization.
[0042] Figure 2 : The effect of antibody #40 before and after humanization in neutralizing orthopoxvirus infection represented by VACV in vitro.
[0043] Figure 3A : The effect of bispecific antibodies in vivo against orthopoxvirus infection represented by VACV, wherein the horizontal axis shows the number of days after infection, and the vertical axis shows the percentage change in weight of mice.
[0044] Figure 3B : The effect of bispecific antibodies in vivo against infection by orthopoxviruses represented by VACV, wherein the horizontal axis shows the number of days after infection, and the vertical axis shows the survival percentage of mice.
[0045] Figure 3C : The effect of bispecific antibodies in vivo against orthopoxvirus infection represented by VACV, wherein the horizontal axis shows the names of the bispecific antibodies and the control, and the vertical axis shows the mouse lung virus load. DETAILED DESCRIPTION
[0046] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.
[0047] Example 1: Humanization of Antibody #40
[0048] The CDR regions of the antibody light and heavy chains were predicted using the IMGT or Kabat database, and the CDR regions of the 40# mouse antibody light and heavy chains were transplanted into the corresponding human antibody light and heavy chain frameworks with the highest homology to the mouse antibody to form humanized antibodies.
[0049] Example 2: Surface plasmon resonance technique to detect the ability of antibodies to bind antigens
[0050] Surface plasmon resonance analysis was performed using Biacore 8K (GE Healthcare). The specific steps were as follows: protein A chip (GE Healthcare) was selected, and the antibody protein was fixed on the chip through the binding of protein A to the antibody Fc. The antibody fixed amount was about 500RU. The antigen protein was diluted in multiples with PBST solution (pH 7.4), and the sample was passed through the chip surface. The changes in the response value were recorded. The kinetic curve and kinetic constant analysis of antibody binding to antigen were performed using BIAevaluation software 8K (GE Healthcare). Figure 1 The results showed that the affinity of antibody 40# before (40) and after (h40) humanization for binding to MPXV M1R was 0.01 nM and 0.02 nM, respectively, with no significant change.
[0051] Example 3: Plaque assay to detect the neutralizing effect of antibodies on VACV virus
[0052] Neutralization of VACV IMV: Dilute the pre-humanized 40# antibody and the humanized h40 antibody 2-fold from 100μg / mL, with a total of 10 dilution gradients; add the diluted virus solution (about 100PFU / well) to each well; incubate the mixture in a 37℃ incubator for 2h; add the incubated antibody and virus mixture to the cells and infect the cells at 37℃ for 1h; discard the mixture, wash the cells once with PBS in each well, then add 1mL (2x DMEM and carboxymethyl cellulose 1:1 mixture), and continue to culture for 48h; add 4% paraformaldehyde fixative to each well and fix for more than 2h; discard the paraformaldehyde, add crystal violet stain to each well, and observe the results after staining for 2h; calculate the neutralization activity value of the antibody according to the number of plaques (PRNT 50 ). The result is Figure 2 As shown, it can be seen that after humanization, antibody #40 can still effectively neutralize VACV virus infection, with an activity of 0.3576 μg / mL.
[0053] Example 4: Anti-VACV virus infection effect of antibodies in vivo
[0054] The in vivo protective effect of the antibody was evaluated using a BALB / c mouse model. A lethal dose of VACV was administered by nasal drops, and the antibody was administered by intraperitoneal injection 4 hours before and after the challenge. The antibody dose was 5 mg / kg. The control group mice were given an irrelevant antibody (targeting SARS-CoV-2) or PBS, and were euthanized when the weight loss exceeded 20%. Figure 3A , Figure 3B and Figure 3C As shown, bispecific antibodies can more significantly reduce the viral load in the lungs of mice, showing a better protective effect.
Claims
1. A bispecific antibody against monkeypox virus, characterized in that: The heavy chain variable region is formed by connecting the heavy chain variable region of the first antibody, the light chain variable region of the second antibody, the heavy chain variable region of the second antibody and a linker; or the heavy chain variable region is formed by connecting the heavy chain variable region of the second antibody, the light chain variable region of the first antibody, the heavy chain variable region of the first antibody and a linker; wherein the three complementary determining regions (CDRs) of the heavy chain variable region of the first antibody have an amino acid sequence selected from the group consisting of: CDR1 as shown in SEQ ID NO: 1, CDR2 as shown in SEQ ID NO: 2, and CDR3 as shown in SEQ ID NO: 3; and the three complementary determining regions (CDRs) of the light chain variable region thereof have an amino acid sequence selected from the group consisting of: CDR1 as shown in SEQ ID NO: 4, CDR2 as shown in SEQ ID NO: 5, and CDR3 as shown in SEQ ID NO: 6; The three complementary determining regions CDRs of the heavy chain variable region of the second antibody have an amino acid sequence selected from the following group: CDR1 as shown in SEQ ID NO:7, CDR2 as shown in SEQ ID NO:8, and CDR3 as shown in SEQ ID NO:9; the three complementary determining regions CDRs of the light chain variable region thereof have an amino acid sequence selected from the following group: CDR1 as shown in SEQ ID NO:10, CDR2 as shown in SEQ ID NO:11, and CDR3 as shown in SEQ ID NO:
12.
2. The monkeypox virus bispecific antibody according to claim 1, characterized in that: The first antibody heavy chain contains a heavy chain variable region as shown in SEQ ID NO: 13, and a light chain variable region as shown in SEQ ID NO: 14; The second antibody comprises a heavy chain variable region as shown in SEQ ID NO:15, and a light chain variable region as shown in SEQ ID NO:
16.
3. The monkeypox virus bispecific antibody according to claim 1 or 2, characterized in that: The heavy chain variable region connection method is that the first antibody heavy chain variable region, the second antibody light chain variable region, the linker, and the second antibody heavy chain variable region are connected in sequence, wherein the positions of the second antibody light chain variable region and the second antibody heavy chain variable region can be exchanged; Alternatively, the connection method is that the second antibody heavy chain variable region, the first antibody light chain variable region, the linker, and the first antibody heavy chain variable region are connected in sequence, wherein the positions of the first antibody light chain variable region and the first antibody heavy chain variable region can be exchanged; preferably, the amino acid sequence of the linker is SEQ ID NO:
17.
4. The monkeypox virus bispecific antibody according to claim 3, characterized in that: The amino acid sequence of its heavy chain variable region is SEQ ID NO:18, and the amino acid sequence of its light chain variable region is SEQ ID NO:14; or the amino acid sequence of its heavy chain variable region is SEQ ID NO:19, and the amino acid sequence of its light chain variable region is SEQ ID NO:
16.
5. The monkeypox virus bispecific antibody according to claim 4, characterized in that: The antibody type is IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; Preferably, the antibody is freed of CDR regions, and the remaining sequences are derived from species including, but not limited to, one or more of mice, rats, guinea pigs, hamsters, rabbits, ferrets, cats, dogs, goats, sheep, cows, pigs, horses, monkeys and humans; Preferably, the antibody further comprises a heavy chain constant region and a light chain constant region; Preferably, the antibody comprises a sequence of a constant region of one of human antibodies IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; Preferably, the amino acid sequence of the heavy chain constant region of the antibody is as shown in SEQ ID NO: 20; Preferably, the amino acid sequence of the light chain constant region of the antibody is as shown in SEQ ID NO:
21.
6. A polynucleotide encoding the monkeypox virus bispecific antibody according to any one of claims 1 to 5. An expression vector comprising the polynucleotide according to claim 6 . A host cell comprising the expression vector according to claim 7 .
9. Use of the monkeypox virus bispecific antibody according to any one of claims 1 to 5 in the preparation of a medicament for treating and preventing orthopoxvirus infection, wherein the orthopoxvirus includes but is not limited to monkeypox virus, vaccinia virus, smallpox virus, and cowpox virus.
10. A pharmaceutical composition comprising the bispecific antibody against monkeypox virus according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier, and optionally further comprising an excipient; Specifically, the dosage form of the pharmaceutical composition is an oral agent or a non-oral agent; more specifically, the oral agent is a tablet, powder, pill, powder, granule, fine granule, soft / hard capsule, film-coated agent, pellet, sublingual tablet, paste, etc.; the non-oral agent is an injection, suppository, transdermal agent, ointment, plaster, external liquid, etc.
Citation Information
Patent Citations
Antibody targeting monkey pox virus, and antigen binding fragment and application thereof
CN117050165A
Monoclonal neutralizing antibody of monkey pox virus and application thereof
CN117466994A
Anti-monkey pox virus antibody or antigen binding fragment thereof and application thereof
CN117659177A
Anti-monkey pox virus antibody as well as preparation method and application thereof
CN117683122A
Monoclonal antibody for resisting monkey pox virus and application thereof
CN118638215A
